CRO launches stat monitoring tech in line with ICH GCP addendum

By Flora Southey

- Last updated on GMT

GettyImages/shironosov
GettyImages/shironosov

Related tags Clinical trial

Quanticate has launched an upgraded statistical monitoring service following the ICH’s good clinical practice (GCP) E6(R2) addendum designed to streamline clinical trials.

The data-focused contract research organisation (CRO) said the service is an extension of its statistical consultancy offering, and responds to recent amendments​ to the International Conference of Harmonisation (ICH) E6(R2) guidelines.

The service – which incorporates a risk-based approach to protocol design and statistical analysis plans in clinical trials – could help ensure the safety of trials by identifying and mitigating risks, said the firm. 

“The objective is to make trials more efficient whilst maintaining high quality and protecting patient safety,” ​said executive vice president Daniel Chapple.

Centralising statistical monitoring​ reduces the need to visit all clinical trial sites for data analysis, he added.

According to the CRO, the service is a cost efficient method of data analysis, and would benefit all companies undertaking clinical trials.

“Our functional outsourcing approach for overseeing multiple programmes would be more relevant for larger customers, but our statistical consultancy and review can be outsourced at an individual study level,” ​Chapple told us. 

Niche CRO interest

Quanticate said niche CROs are increasingly looking to streamline clinical data management and analysis.

“Having no link to the investigator sites, the sponsor, the CRO overseeing the site relationship or the principal investigators means that the data quality checks are completely unbiased,” ​Chapple said.

“It adds additional confidence since the ICH guidelines are clear that the sponsor is ultimately responsible for the data regardless of who they outsource to,” ​he added.

ICH is inviting public review and comment on a reflection paper​ on GCP ‘Renovation,’ to provide updated guidance that it says is “both flexible enough to address the increasing diversity of study types and data sources that are being employed to support regulatory and other health policy decisions.”

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us

Products

View more

Webinars